A federal judge in Boston has delivered a sharp judicial setback to the overhaul of childhood vaccination policies pushed by Robert F. Kennedy Jr., blocking key changes that sought to reduce the number of routine vaccines for children and reshape a powerful advisory body guiding national immunization policy.
In a detailed ruling, Brian Murphy, a judge of the United States District Court for the District of Massachusetts, concluded that the process used to alter vaccine recommendations and restructure the government’s vaccine advisory committee violated established legal procedures.
The decision came in response to a challenge from the American Academy of Pediatrics and several medical organizations. They argued that the federal government had moved ahead with sweeping vaccine policy changes without following the safeguards designed to ensure scientific integrity and transparency in public health decisions.
Advisory Panel Appointments Blocked
At the centre of the dispute was the Advisory Committee on Immunization Practices, the influential expert panel that shapes vaccination guidelines followed across the United States.
The court barred 13 individuals appointed to the committee under Kennedy from continuing in their roles and nullified several decisions taken by the reconstituted body. Because of the ruling, an upcoming meeting of the panel was postponed.
The judge found that the committee had been improperly formed after previous members were removed and replaced. According to the ruling, the new panel lacked the scientific balance and expertise required under federal law.
Murphy observed that for decades vaccination policy in the United States had been built through a structured process grounded in scientific review and procedural safeguards. Departing from those standards, he wrote, risks undermining the credibility of public health actions.
Changes to Immunization Schedule Questioned
The controversy began earlier this year when the Centers for Disease Control and Prevention announced revisions to the childhood immunization schedule. The move reduced the number of routinely recommended vaccines and softened recommendations for several diseases, including rotavirus, influenza and hepatitis A.
Medical groups challenged the decision, arguing that the agency lacked authority to make such changes without first consulting the advisory committee. The court agreed, stating that the CDC could not unilaterally alter the schedule outside the framework established for vaccine policy review.
Panel’s Earlier Decisions Also Voided
Because the judge determined the committee had been improperly constituted, earlier votes by the body were also set aside. These included decisions to scale back recommendations for hepatitis B vaccinations for newborns and certain COVID-19 shots.
The ruling noted that only a small portion of the current committee members appeared to have significant professional experience in vaccines or immunization research—expertise normally required for the panel’s work.
Reactions Across the Public Health Landscape
Medical and scientific groups welcomed the decision, describing it as a step toward restoring established public health processes.
Officials aligned with Kennedy’s “Make America Healthy Again” movement criticized the ruling, portraying it as an example of judicial overreach and signalling that the administration is likely to challenge the decision in a higher court.
The Department of Health and Human Services defended the broader policy agenda, arguing that vaccine policy should remain flexible amid declining public confidence following the COVID-19 pandemic.
Industry and Policy Implications
The legal battle is being closely watched by vaccine manufacturers, including companies such as Pfizer, Moderna, Merck & Co., Sanofi, and GlaxoSmithKline, whose products form the backbone of the childhood immunization schedule.
While the judge blocked several policy changes, one directive remains untouched for now: an earlier order halting recommendations for COVID-19 vaccines for healthy children and pregnant women.
The case marks a significant moment in the ongoing clash between public health institutions and political efforts to reshape vaccine policy in the United States, a debate that is increasingly spilling into courts, legislatures, and clinics across the country.
